In­dus­try gets the edge: Medicare drug price ne­go­ti­a­tions will on­ly cost bio­phar­ma 10 drugs over the next 30 years

The House on Fri­day morn­ing passed a bill that will al­low Medicare to ne­go­ti­ate pre­scrip­tion drug prices for a lim­it­ed num­ber of sin­gle source drugs, but it’s a deal that will on­ly make a mi­nor dent in the pock­et­book of the bio­phar­ma in­dus­try.

The ne­go­ti­a­tions and oth­er pric­ing pro­vi­sions, like in­sulin and se­nior out-of-pock­et caps, are part of a sprawl­ing $1.8 tril­lion spend­ing pack­age that the De­moc­rats and Biden have been push­ing for all sum­mer. The bill, which re­lies on the phar­ma-re­lat­ed sav­ings to help pay for it, now moves to the Sen­ate.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.